Gyeongseon Shin

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Optimizing hepatitis C micro-elimination in forensic psychiatric settings: Cost-effectiveness of screening strategies in Korea.

Optimizing hepatitis C micro-elimination in forensic psychiatric settings: Cost-effectiveness of screening strategies in Korea.

Journal: Journal of infection and public health

Published: May 06, 2026

How Long Should We Wait? The Impact of Immature Data on Colorectal Cancer Decision Modeling.

How Long Should We Wait? The Impact of Immature Data on Colorectal Cancer Decision Modeling.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: December 16, 2025

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability.

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability.

Journal: Frontiers in pharmacology

Published: July 04, 2025

Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?

Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: April 07, 2025

Unaware and unpowered: evaluating patient perceptions and preferences of biosimilars in South Korea.

Unaware and unpowered: evaluating patient perceptions and preferences of biosimilars in South Korea.

Journal: Frontiers in pharmacology

Published: December 25, 2024

HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on "Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness".

HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on "Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness".

Journal: Clinical and molecular hepatology

Published: November 23, 2024

Quantifying social contact dynamics in South Korea in the post-COVID-19 endemic phase: A cross-sectional survey for infectious disease transmission.

Quantifying social contact dynamics in South Korea in the post-COVID-19 endemic phase: A cross-sectional survey for infectious disease transmission.

Journal: Journal of infection and public health

Published: October 17, 2024

Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness.

Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness.

Journal: Clinical and molecular hepatology

Published: June 26, 2024

Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries.

Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: January 22, 2024

Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study.

Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: December 11, 2023

Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.

Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: November 16, 2023

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Journal: International journal of environmental research and public health

Published: August 12, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026